Treatment and follow-up of low-risk patients with thyroid cancer
- 9 August 2011
- journal article
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 7 (10) , 625-628
- https://doi.org/10.1038/nrendo.2011.133
Abstract
The postoperative administration of radioiodine can be avoided in low-risk patients with undetectable TSH-stimulated serum thyroglobulin and no lymph-node metastases detected at surgery. Sensitive methods for serum thyroglobulin determination can be used to avoid TSH stimulation 9-12 months after surgery in low-risk patients who have an undetectable serum thyroglobulin on levothyroxine treatment; the role of these sensitive assays in the period immediately after surgery needs to be established by further studies. Finally, a low activity of radioiodine (1.1 GBq) should be administered selectively in low-risk patients receiving levothyroxine treatment following injections of recombinant human TSH. These modifications of current protocols will improve the quality of life of patients, potentially decrease morbidity and considerably reduce the cost of treatment and follow-up.Keywords
This publication has 67 references indexed in Scilit:
- Long-Term Follow-Up of Patients with Papillary and Follicular Thyroid Cancer: A Prospective Study on 715 PatientsJournal of Clinical Endocrinology & Metabolism, 2011
- Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin levelEndocrine-Related Cancer, 2010
- Radioiodine Therapy in Patients with Stage I Differentiated Thyroid CancerThyroid®, 2010
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2009
- Prophylactic Lymph Node Dissection for Papillary Thyroid Cancer Less Than 2 cm: Implications for Radioiodine TreatmentJournal of Clinical Endocrinology & Metabolism, 2009
- Ultrasound Criteria of Malignancy for Cervical Lymph Nodes in Patients Followed Up for Differentiated Thyroid CancerJournal of Clinical Endocrinology & Metabolism, 2007
- Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low‐risk patients with thyroid cancer with Tg on T4 < 1 ng/ml determined by traditional assays?Clinical Endocrinology, 2007
- Comparison of Seven Serum Thyroglobulin Assays in the Follow-Up of Papillary and Follicular Thyroid Cancer PatientsJournal of Clinical Endocrinology & Metabolism, 2007
- Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humansHuman Immunology, 2005
- Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3 The Journal of Experimental Medicine, 2003